Covid-19 roundup: Synair­gen turns to post-hoc analy­ses af­ter failed drug tri­al; EU ter­mi­nates Val­ne­va vac­cine con­tract

Af­ter halt­ing en­roll­ment in an NIH-led Phase II/III study, and fail­ing an ear­li­er Phase III tri­al, UK-based Synair­gen’s Covid-19 drug did show some promise in some se­lect sub­groups, the com­pa­ny said in its pre­sen­ta­tion of a post-hoc analy­sis on Mon­day at a con­fer­ence in San Fran­cis­co.

Post-hoc analy­ses of the Phase III SPRINT­ER tri­al, which failed to hit its pri­ma­ry end­points, showed an “en­cour­ag­ing sig­nal in re­duc­tion in the rel­a­tive risk (RRR) of pro­gres­sion to se­vere dis­ease or death with­in 35 days (25.7% re­duc­tion in the In­ten­tion-to-Treat pop­u­la­tion and 36.3% re­duc­tion in the Per Pro­to­col pop­u­la­tion).”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN